Pericapsular fibrotic overgrowth mitigated in immunocompetent mice through microbead formulations based on sulfated or intermediate G alginates
Source abstract
Abstract
Cell encapsulation in alginate microbeads is a promising approach to provide immune isolation in cell therapy without immunosuppression. However, the efficacy is hampered by pericapsular fibrotic overgrowth (PFO), causing encapsulated cells to lose function. Stability of the microbeads is important to maintain immune isolation in the long-term. Here, we report alginate microbeads with minimal PFO in immunocompetent C57BL/6JRj mice. Microbead formulations included either alginate with an intermediate (47 %) guluronate (G) content (IntG) or sulfated alginate (SA), gelled in Ca2+/Ba2+ or Sr2+. A screening panel of eleven microbead formulations were evaluated for PFO, yielding multiple promising microbeads. Two candidate formulations were evaluated for 112 days in vivo, exhibiting maintained stability and minimal PFO. Microbeads investigated in a human whole blood assay revealed low cytokine and complement responses, while SA microbeads activated coagulation. Protein deposition on microbeads explanted from mice investigated by confocal laser scanning microscopy (CLSM) showed minimal deposition of complement C3. Fibrinogen was positively associated with PFO, with a high deposition on microbeads of high G (68 %) alginate compared to IntG and SA microbeads. Overall, stable microbeads containing IntG or SA may serve in long-term therapeutic applications of cell encapsulation. STATEMENT OF SIGNIFICANCE: Alginate-based hydrogels in the format of micrometer size beads is a promising approach for the immunoisolation of cells in cell therapy. Clinical trials in type 1 diabetes have so far had limited success due to fibrotic responses that hinder the diffusion of nutrients and oxygen to the encapsulated cells, resulting in graft failure. In this study, minimal fibrotic response towards micrometer size alginate beads was achieved by chemical modification of alginate with sulfate groups. Also, the use of alginate with intermediate guluronic acid content resulted in minimally fibrotic microbeads. Fibrinogen deposition was revealed to be a good indicator of fibrosis. This study points to both new microsphere developments and novel insight in the mechanisms behind the fibrotic responses.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Pancreatic function and diabetes · 3D Printing in Biomedical Research · Hydrogels: synthesis, properties, applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (58)
Show source-provided references
1. Current and future perspectives on alginate encapsulated pancreatic islet10.1002/sctm.16-0116 ↗
2. Advances in biocompatibility and physico-chemical characterization of microspheres for cell encapsulation10.1016/j.addr.2013.07.010 ↗
3. Safety and viability of microencapsulated human islets transplanted into diabetic humans10.2337/dc09-0744 ↗
4. Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient10.1007/s00125-013-2906-0 ↗
5. Foreign body reaction to biomaterials10.1016/j.smim.2007.11.004 ↗
6. Colony stimulating factor-1 receptor is a central component of the foreign body response to biomaterial implants in rodents and non-human primates10.1038/nmat4866 ↗
7. Size and shape-dependent foreign body immune response to materials implanted in rodents and non-human primates10.1038/nmat4290 ↗
8. Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates10.1038/nbt.3462 ↗
9. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques10.1038/s41551-018-0275-1 ↗
10. Zwitterionically modified alginates mitigate cellular overgrowth for cell encapsulation10.1038/s41467-019-13238-7 ↗
11. Factors influencing alginate gel biocompatibility10.1002/jbm.a.33047 ↗
12. The effect of host factors and capsule composition on the cellular overgrowth on implanted alginate capsules10.1002/1097-4636(20011205)57:3<374::AID-JBM1180>3.0.CO;2-L ↗
13. Poly-L-Lysine induces fibrosis on alginate microcapsules via the induction of cytokines10.3727/000000001783986800 ↗
14. Alginate microsphere compositions dictate different mechanisms of complement activation with consequences for cytokine release and leukocyte activation10.1016/j.jconrel.2016.03.021 ↗
15. Alginate microbeads are coagulation compatible, while alginate microcapsules activate coagulation secondary to complement or directly through FXII10.1016/j.actbio.2017.05.052 ↗
16. The induction of cytokines by polycation containing microspheres by a complement dependent mechanism10.1016/j.biomaterials.2012.10.012 ↗
17. Vitro and in vivo biocompatibility evaluation of polyallylamine and macromolecular heparin conjugates modified alginate microbeads
18. Alginate microbeads are complement compatible, in contrast to polycation containing microcapsules, as revealed in a human whole blood model10.1016/j.actbio.2011.03.011 ↗
19. Effect of Ca2+, Ba2+, and Sr2+ on alginate microbeads10.1021/bm060010d ↗
20. Encapsulation of human islets in novel inhomogeneous alginate-Ca2+/Ba2+ microbeads: in vitro and in vivo function. artificial cells10.1080/10731190802369755 ↗
21. Binding and leakage of barium in alginate microbeads10.1002/jbm.a.34237 ↗
22. Sulfated alginate microspheres associate with factor H and dampen the inflammatory cytokine response10.1016/j.actbio.2016.06.015 ↗
23. Microencapsulated islet allografts in diabetic NOD mice and nonhuman primates
24. A p.m.r. study of the composition and sequence of uronate residues in alginates10.1016/S0008-6215(00)84051-3 ↗
25. High-field, 1H-n.m.r. spectroscopy of alginate: sequential structure and linkage conformations10.1016/0008-6215(83)88053-7 ↗
26. A study of the chain stiffness and extension of alginates, in vitro epimerized alginates, and periodate-oxidized alginates using size-exclusion chromatography combined with light scattering and viscosity detectors10.1021/bm060099n ↗
27. Heparin-like properties of sulfated alginates with defined sequences and sulfation degrees10.1021/bm500602w ↗
28. The impact of chain length and flexibility in the interaction between sulfated alginates and HGF and FGF-210.1021/acs.biomac.5b01125 ↗
29. Microcapsules made by enzymatically tailored alginate10.1002/jbm.a.10337 ↗
30. Homogeneous alginate gels: a technical approach10.1016/0144-8617(90)90028-Q ↗
31. Properties of poly(1,4-hexuronates) in the gel state. I. evaluation of a method for the determination of stiffness10.3891/acta.chem.scand.26-0079 ↗
32. Alginate as immobilization material: I. correlation between chemical and physical properties of alginate gel beads10.1002/bit.260330111 ↗
33. Effect of prolonged gelling time on the intrinsic properties of barium alginate microcapsules and its biocompatibility10.3109/02652048.2011.586067 ↗
34. Essential role of the C5a receptor in E coli–induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation
35. Control of matrix stiffness using methacrylate–gelatin hydrogels for a macrophage-mediated inflammatory response10.1021/acsbiomaterials.0c00295 ↗
36. Alginate polycation microcapsules: I. Interaction between alginate and polycation10.1016/0142-9612(96)84680-1 ↗
37. Alginate polycation microcapsules: II. Some functional properties10.1016/0142-9612(96)85907-2 ↗
38. Hydrogels for tissue engineering10.1021/cr000108x ↗
39. Growth factors, matrices, and forces combine and control stem cells10.1126/science.1171643 ↗
40. Ca2+ released from calcium alginate gels can promote inflammatory responses in vitro and in vivo10.1016/j.actbio.2013.08.002 ↗
41. Use of alginate matrices to control cell growth
42. Sulfated alginates as heparin analogues: a review of chemical and functional properties10.3390/molecules22050778 ↗
43. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators10.1038/ni.1755 ↗
44. Insights into the effects of complement factor H on the assembly and decay of the alternative pathway C3 proconvertase and C3 convertase10.1074/jbc.M115.693119 ↗
45. The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins10.1016/j.biomaterials.2008.04.025 ↗
46. Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18)10.1161/01.CIR.100.14.1533 ↗
47. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents10.1172/JCI1509 ↗
48. Pharmacology of heparin and related drugs10.1124/pr.115.011247 ↗
49. Structural characterization of fucoidan from laminaria hyperborea: assessment of coagulation and inflammatory properties and their structure–function relationship10.1021/acsabm.8b00436 ↗
50. The surface topography of silicone breast implants mediates the foreign body response in mice, rabbits and humans10.1038/s41551-021-00739-4 ↗
51. Hydrogel microspheres: influence of chemical composition on surface morphology, local elastic properties, and bulk mechanical characteristics10.1021/la048389h ↗
52. Fibrin(ogen) mediates acute inflammatory responses to biomaterials10.1084/jem.178.6.2147 ↗
53. Histamine release and fibrinogen adsorption mediate acute inflammatory responses to biomaterial implants in humans10.1186/1479-5876-5-31 ↗
54. Fibrin mechanisms and functions in nervous system pathology
55. Molecular determinants of acute inflammatory responses to biomaterials10.1172/JCI118549 ↗
56. Mechanical properties of C-5 epimerized alginates10.1021/bm8003572 ↗
57. Induction of cytokine production from human monocytes stimulated with alginate10.1097/00002371-199108000-00007 ↗
58. Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers10.1074/jbc.M201366200 ↗